Industry: Biotechnology (See others in industry)
Address:Date | FilingType | Incremental Cash | Link to Raw Filing | |||
---|---|---|---|---|---|---|
2025-07-02 | New | $808,000 | $808,000 | Equity Only | 06b | SEC link |
2024-11-15 | New | $900,000 | $900,000 | Equity Only | 06b | SEC link |
2024-06-12 | New | $1,100,000 | $1,100,000 | Equity Only | 06b | SEC link |
2023-12-11 | New | $1,500,000 | $1,500,000 | Equity Only | 06b | SEC link |
2022-10-06 | New | $2,390,000 | $2,390,000 | Equity Only | 06b | SEC link |
2022-02-23 | New | $1,807,117 | $1,807,117 | Equity Only | 06b | SEC link |
2020-07-13 | New | $455,260 | $455,260 | Equity Only | 06b | SEC link |
2019-11-18 | New | $439,244 | $439,244 | Equity Only | 06b | SEC link |
2019-02-19 | New | $3,050,609 | $3,050,609 | Equity Only | 06b | SEC link |
2015-12-17 | New | $502,408 | $502,408 | Equity Only | 06b | SEC link |
2006-06-02 | Paper Filing | Unknown | Unknown | Other | Not Available |
Name | Role |
---|---|
David Arslanian | Director |
Blaine Crissman | Director |
Michael Goldstein | Director |
George Holmes | Director |
Kent Lehr | Director |
Peter D Los | Director |
Randall Marfin | Director |
James E Oury | Executive |
Katie Pohlson | Director |
Kamran Tahamtanzade | Director |
David Ure | Director, Executive |